›@ŠwZ‹‹H‚Ö
. ‘Ž‰–b –O˜aŽ‰–b ƒgƒ‰ƒ“ƒXŽ‰–b ƒRƒŒƒXƒeƒ[ƒ‹
¢ŠE•ÛŒ’‹@\WHO‚Ì–Ú•W—Ê 15-30% 10%–¢–ž 1%–¢–ž 300mg/“ú–¢–ž
•Ä‘S‘Ÿ‹¦‰ïAHA‘ål‚Ì–Ú•W—Ê . 7%–¢–ž 1%–¢–ž 300mg/“ú–¢–ž
•Ä‘S‘Ÿ‹¦‰ïAHA4-18΂̖ڕW—Ê 25-35% ­‚È‚­ ­‚È‚­ .
•Ä‘ŠwZ‹‹H‚ÌŠî€ 30%ˆÈ‰º 10%–¢–ž . ­‚È‚­
‰p‘ŠwZ‹‹H‚ÌŠî€ 35%ˆÈ‰º 11%ˆÈ‰º 2%ˆÈ‰º .
“ú–{l‚ÌHŽ–ÛŽæŠî€ . . . .
30-69Î@’j« 20-25% 4.5-7.0% . 750mg/“ú–¢–ž
30-69Î@—« 20-25% 4.5-7.0% . 600mg/“ú–¢–ž
18-29Î@’j« 20-30% 4.5-7.0% . 750mg/“ú–¢–ž
18-29Î@—« 20-30 4.5-7.0% . 600mg/“ú–¢–ž
6-17Î ’j« 20-30% . . .
6-17Î —« 20-30% . . .
“Œ‹ž“sŠwZ‹‹H‚ÌŠî€ 25-30% . . .